



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 June 2017
EMA/CHMP/ICH/308867/2008
Committee for Human Medicinal Products

ICH guideline Q4B Annex 4C on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use

Step

Transmission to CHMP	June 2008
Transmission to interested parties	June 2008
Deadline for comments	September 2008
Final approval by CHMP	December 2008
Date for coming into operation	June 2009



ICH guideline Q4B Annex 4C on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use

Table of contents

1. Introduction	3
2. Q4B Outcome	3
3. Timing of annex implementation	3
4. Considerations for implementation.....	3
4.1. General consideration	3
4.2. FDA consideration	3
4.3. EU consideration	3
4.4. MHLW consideration	4
4.5. Health Canada consideration.....	4
5. References used for the Q4B evaluation	4
5.1. The PDG Stage 5B sign-off document.....	Error! Bookmark not defined.
5.2. The pharmacopoeial references for Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use for this annex	Error! Bookmark not defined.
5.2.1. European Pharmacopoeia (Ph. Eur.)	Error! Bookmark not defined.
5.2.2. Japanese Pharmacopoeia (JP)	Error! Bookmark not defined.
5.2.3. United States Pharmacopeia (USP)	Error! Bookmark not defined.

1. Introduction

This annex is the result of the Q4B process for Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use.

For each regulatory region, the pharmacopoeial text is non-mandatory and is provided for informational purposes only.

The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

2. Q4B outcome

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 5.1.4. Microbiological Quality of Non-Sterile Pharmaceutical Preparations and Substances for Pharmaceutical Use, JP General Information 12. Microbial Attributes of Non-sterile Pharmaceutical Products, and USP <1111> Microbiological Attributes of Nonsterile Pharmaceutical Products, can be used as interchangeable in the ICH regions.

3. Timing of annex implementation

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

4. Considerations for implementation

4.1. General consideration

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

4.2. FDA consideration

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

4.3. EU consideration

For the European Union, the monographs of the Ph. Eur. have mandatory applicability. Regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 5.1.4. on the basis of the declaration of interchangeability made above.

4.4. MHLW consideration

The pharmacopoeial texts referenced in Section 2 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

4.5. Health Canada consideration

In Canada any of the pharmacopoeial texts cited in Section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

5. References used for the Q4B evaluation

5.1 The PDG Stage 5B sign-off document:

Japanese Pharmacopoeial Forum, Volume 14, Number 4 (December 2005)

5.2 The pharmacopoeial references for Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use for this annex are:

5.2.1 European Pharmacopoeia (Ph. Eur.): 6.3 Edition (official on January 2009) Microbiological Quality of Non-Sterile Pharmaceutical Preparations and Substances for Pharmaceutical Use (reference 01/2009: 50104).

5.2.2 Japanese Pharmacopoeia (JP): JP General Information 12. Microbial Attributes of Non-sterile Pharmaceutical Products as it appears in Supplement I to the Japanese Pharmacopoeia Fifteenth Edition (September 28, 2007, Notification PFSB No. 0928001). The English version was published on January 9, 2008.

5.2.3 United States Pharmacopeia (USP): <1111> Microbiological Attributes of Nonsterile Pharmaceutical Products official in USP 30, January 2007.